Skip to main content
CHMMF logo

Chimeric Therapeutics Limited (CHMMF) Stock Price & Analysis

Chimeric Therapeutics Limited (CHMMF) — price $0.10 (0.00%), as of the Nov 19, 2026 trading session; market cap $14.8M.

Educational signal · not a buy or sell recommendation · How to read this

$0.10 $0.00 (0.00%) Market Cap $14.8M

Chimeric Therapeutics Limited · CHMMF

Chimeric Therapeutics Limited is an Australian clinical-stage cell therapy company focused on developing and commercializing innovative oncology treatments. Their pipeline includes CAR-T and NK cell therapies targeting various solid tumors and hematological malignancies.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.10
Change on the day0.00%
Market capitalisation$14.8M—
Shares traded on the day30.0K

Price & events

Other perspectives

Council score for Chimeric Therapeutics (CHMMF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 13, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Chimeric Therapeutics (CHMMF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Chimeric Therapeutics Limited (CHMMF) is the company analyzed here. In Q4 FY2025 it reported revenue of A$7M and net income of -A$8M. The market values it at $14.8M.

2 · Latest results

What do the latest results show for Chimeric Therapeutics (CHMMF)?

Short answer · as of

The most recent reported quarter, Q4 FY2025, carried revenue of A$7M. Against analyst estimates the company has EPS beat 3 of the last 4 reports.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2025A$7M-A$8M-A$0.45 (diluted)
Q2 FY2025A$6M-A$3M-A$0.28 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Chimeric Therapeutics (CHMMF)?

Short answer · as of

The distress and quality screens read Piotroski F 2. Trailing ratios: ROE 349.9% · current ratio 0.12.

4 · What to check next?

What should you watch next at Chimeric Therapeutics (CHMMF)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $378.69M · EPS 0.00 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q4 FY2025) was filed Jun 30, 2025 — 8 months ago.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$378.69M
EPS estimate
$0.00

Measured against a quoted price of $0.10 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CHMMF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CHMMF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Chimeric Therapeutics (CHMMF)

These answers are editorial: 1 of these 8 answers is drawn from the CHMMF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is CHMMF a good stock to buy?

Stock Expert AI does not rate CHMMF buy, sell or hold. Chimeric Therapeutics Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CHMMF stock price today?

The last price recorded for Chimeric Therapeutics Limited (CHMMF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for CHMMF?

The primary risks for Chimeric Therapeutics Limited revolve around the inherent challenges of clinical-stage drug development. Clinical trial failures or delays represent a significant threat, as positive data is crucial for attracting investment and advancing therapies towards regulatory approval.

What are the key factors to evaluate for CHMMF?

Evaluate CHMMF on fundamentals, analyst consensus, and risk factors. Chimeric Therapeutics is a clinical-stage cell therapy company focused on oncology, developing both CAR-T and NK cell therapies. Not financial advice.

How frequently does CHMMF data refresh on this page?

CHMMF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CHMMF's recent stock price performance?

Chimeric Therapeutics Limited (CHMMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary CAR-T and NK cell therapy platforms. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CHMMF overvalued or undervalued right now?

Chimeric Therapeutics Limited (CHMMF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CHMMF before investing?

Before investing in Chimeric Therapeutics Limited (CHMMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.